Stocks-Prognosis.com
Search on StockPrognosis.com
To search on the site stockprognosis.com enter the name of the ticker, company name, or search phrase
Sections of the site



AbbVie ABBV to Acquire Nimble Therapeutics Further Strengthening Immunology Pipeline

December 20, 2024
AbbVie Inc. (NYSE: ABBV) has announced its plans to acquire Nimble Therapeutics, a biotechnology company specializing in antibody drug discovery. This acquisition is expected to further strengthen AbbVie's immunology pipeline and expand its capabilities in developing innovative therapies for various diseases. The deal is set to provide AbbVie with access to Nimble's proprietary chemical-genetic discovery platform, which can efficiently screen and identify potential therapeutic antibodies. With this acquisition, AbbVie aims to continue its mission of delivering groundbreaking treatments for patients worldwide. Investors and industry experts are closely watching AbbVie's strategic moves, recognizing the company's potential for significant growth in the future. Stocks Prognosis recommends considering the purchase of AbbVie shares, as the company continues to expand its portfolio and demonstrate its commitment to innovation.
If you want to leave a comment, then you need Login or Register





Other data for ABBV

Related data

ABBVMarch 22, 2025AbbVie ABBV Stock Moves -0.29: What You Should Know  ~1 min.

AbbVie Inc., a renowned pharmaceutical company, has recently experienced a slight decrease in stock movement. As an investor, it is essential to keep track of such fluctuations....

ABBVMarch 20, 2025AbbVie Inc. ABBV is Experiencing Global Investor Interest: A Look into the Company's Success Story  ~2 min.

AbbVie Inc., a renowned pharmaceutical company, has been making waves in the global market, attracting significant attention from investors worldwide....

ABBVMarch 19, 2025AbbVie Inc. ABBV: A Higher-Yielding Healthcare Play That Continues to Shine  ~1 min.

AbbVie Inc., a renowned pharmaceutical company, is steadily gaining the attention of investors. With its continuous success in the healthcare industry, AbbVie has become a top choice for hedge funds....

ABBVMarch 18, 2025The Zacks Analyst Blog Highlights AbbVie, Lockheed Martin, Dell, and Hamilton Beach Brands  ~1 min.

According to a recent analysis by Zacks, AbbVie Inc. (ABBV) is considered one of the top healthcare stocks to invest in....

ABBVMarch 14, 2025AbbVie Inc. ABBV is Attracting Investor Attention: Here is What You Should Know  ~2 min.

AbbVie Inc. (ABBV) has been grabbing the attention of investors recently with its impressive performance in the healthcare sector....

ABBVMarch 10, 2025ABBVIE INC. Hits Price Target Forecast with 15.28% Profit – A Triumph for QuantWave's Analytics  ~1 min.

ABBVIE INC. achieved a significant milestone as it hit the price target forecast set by QuantWave, resulting in a profit of 15.28%....

ABBVMarch 10, 2025ABBVIE INC. Hits Price Target Forecast on QuantWave with 15.28% Profit Margin  ~1 min.

AbbVie Inc. (ABBV) has successfully reached the price target forecast on QuantWave, signaling a profitable long position for investors. The forecast, initiated on August 13, 2024, at a price of $184....

ABBVFebruary 28, 2025QuantWave Forecast Success: ABBVIE INC. Hits Price Target with 13.87% Profit  ~2 min.

On July 30, 2024, QuantWave issued a long signal for ABBVIE INC. stock when it was priced at 180.33 $....

ABBVFebruary 28, 2025ABBVIE INC. Hits Price Target Forecast with 25.02% Profit on QuantWave  ~1 min.

QuantWave, the automated forecasting platform, recently achieved a significant milestone with its price target forecast for ABBVIE INC....

ABBVFebruary 27, 2025ABBVIE INC. Hits Price Target Forecast with 22.62% Profit Margin  ~1 min.

QuantWave's forecast for ABBVIE INC. proved to be spot on as the stock reached the predicted target with a profitable outcome of 22.62%....

ABBVDecember 18, 2024AbbVie Inc. ABBV to Acquire Nimble Therapeutics in a Game-Changing Move  ~1 min.

AbbVie Inc., a leading biopharmaceutical company, has announced its acquisition of Nimble Therapeutics, a pioneer in the field of immunology....

ABBVDecember 17, 2024AbbVie Inc. ABBV to Acquire Nimble Therapeutics, Boosting Immunology Pipeline  ~1 min.

AbbVie Inc., a renowned pharmaceutical company, has recently announced its plan to acquire Nimble Therapeutics, a leading biotechnology company, in a move to strengthen its already robust immunology pipeline....

ABBVJanuary 29, 2025AbbVie Inc. Completes Acquisition of Nimble Therapeutics  ~2 min.

AbbVie Inc., a global biopharmaceutical company, has successfully completed its acquisition of Nimble Therapeutics, a biotherapeutics discovery company....

AMGNApril 22, 2025Amgen Inc. AMGN: Among the Innovative Healthcare Stocks to Watch in 2025  ~2 min.

Amgen Inc., a leading biotechnology company, is currently one of the most promising stocks in the healthcare sector....

REGNMarch 16, 2025JIM CRAMER ENCOURAGES INVESTORS TO OWN REGENERON PHARMACEUTICALS INC.  ~2 min.

In the latest episode of Mad Money, renowned financial expert Jim Cramer expressed his bullish stance on Regeneron Pharmaceuticals Inc. (REGN)....